1. Home
  2. DELL vs SNY Comparison

DELL vs SNY Comparison

Compare DELL & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dell Technologies Inc.

DELL

Dell Technologies Inc.

N/A

Current Price

$149.82

Market Cap

84.7B

Sector

Technology

ML Signal

N/A

Logo Sanofi ADS

SNY

Sanofi ADS

N/A

Current Price

$43.69

Market Cap

116.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DELL
SNY
Founded
1984
1994
Country
United States
France
Employees
N/A
74846
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
84.7B
116.8B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
DELL
SNY
Price
$149.82
$43.69
Analyst Decision
Buy
Buy
Analyst Count
15
6
Target Price
$165.86
$61.50
AVG Volume (30 Days)
7.8M
4.1M
Earning Date
05-28-2026
01-01-0001
Dividend Yield
1.43%
3.64%
EPS Growth
N/A
N/A
EPS
5.34
N/A
Revenue
$95,567,000,000.00
N/A
Revenue This Year
$21.52
$3.01
Revenue Next Year
$10.92
$5.80
P/E Ratio
$27.58
$6.14
Revenue Growth
N/A
N/A
52 Week Low
$66.25
$43.51
52 Week High
$168.08
$59.17

Technical Indicators

Market Signals
Indicator
DELL
SNY
Relative Strength Index (RSI) 66.73 32.23
Support Level $145.09 N/A
Resistance Level $152.70 $48.97
Average True Range (ATR) 6.15 0.68
MACD 1.38 -0.36
Stochastic Oscillator 90.87 6.20

Price Performance

Historical Comparison
DELL
SNY

About DELL Dell Technologies Inc.

Dell Technologies is a broad information technology vendor, primarily supplying hardware to enterprises. It focuses on premium and commercial personal computers, as well as enterprise on-premises data center hardware. It holds top-three market shares in its core markets of personal computers, peripheral displays, mainstream servers, and external storage. Dell has a robust ecosystem of component and assembly partners, and also relies heavily on channel partners to fulfill its sales.

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Share on Social Networks: